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Abstract
Background: Surfactant protein D (SP-D) plays an important role in innate defense against
influenza A viruses (IAVs) and other pathogens.
Methods: We tested antiviral activities of recombinant human SP-D against a panel of IAV strains
that vary in glycosylation sites on their hemagglutinin (HA). For these experiments a recombinant
version of human SP-D of the Met11, Ala160 genotype was used after it was characterized
biochemically and structurally.
Results: Oligosaccharides at amino acid 165 on the HA in the H3N2 subtype and 104 in the H1N1
subtype are absent in collectin-resistant strains developed in vitro and are important for mediating
antiviral activity of SP-D; however, other glycans on the HA of these viral subtypes also are involved
in inhibition by SP-D. H3N2 strains obtained shortly after introduction into the human population
were largely resistant to SP-D, despite having the glycan at 165. H3N2 strains have become steadily
more sensitive to SP-D over time in the human population, in association with addition of other
glycans to the head region of the HA. In contrast, H1N1 strains were most sensitive in the 1970s–
1980s and more recent strains have become less sensitive, despite retaining the glycan at 104. Two
H5N1 strains were also resistant to inhibition by SP-D. By comparing sites of glycan attachment on
sensitive vs. resistant strains, specific glycan sites on the head domain of the HA are implicated as
important for inhibition by SP-D. Molecular modeling of the glycan attachment sites on HA and the
carbohydrate recognition domain of SPD are consistent with these observations.
Conclusion: Inhibition by SP-D correlates with presence of several glycan attachment sites on the
HA. Pandemic and avian strains appear to lack susceptibility to SP-D and this could be a
contributory factor to their virulence.
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Influenza A viruses (IAVs) remain a major cause of mor-
bidity and mortality and have the potential to cause mas-
sive mortality if novel pandemic strains emerge through
reassortment of human and avian strains or direct adapta-
tion of avian strains to humans (as appears to have
occurred in 1918) [1,2]. Certain groups of subjects are
known to be more susceptible to adverse effects of influ-
enza infection, including the very young and old, and sub-
jects with a variety of co-morbid conditions [3]. It is likely
that innate host defense mechanisms play an important
role in defense against novel strains associated with anti-
genic drift or shift. These defense mechanisms may play a
greater role in more vulnerable subjects (e.g., those who
are immunocompromised in other ways).
We and others have extensively studied the role of col-
lectins in the early defense against influenza [4-8]. Mice
lacking either SPA or SP-D experience greater viral replica-
tion, inflammation and illness in the first several days
after infection with IAV strains known to be susceptible to
inhibition by these host defense lectins in vitro [4,9,10].
Host defense against IAV can be restored in these mice by
instillation or over-expression of wild type forms of rat SP-
D. Removal of SP-D from human bronchoalveolar lavage
fluid strongly reduces its ability inhibit recent human
strains of IAV [5].
There are several polymorphic forms of SP-D. One of
these involves a variation between Thr and Met at amino
acid 11 in the N-terminus and another between Ala and
Thr at amino acid 160. The identity of the amino acid 11
affects serum levels and resistance to infections (e.g., res-
piratory syncytial virus or Mycobacterium tuberculosis) in
vivo [11-13]. Individuals homozygous for the Thr11 form
of SP-D (~18% in several studies) have lower serum levels
of SP-D and a greater proportion of their SP-D is in the
form of trimers as compared to individuals with the
Met11 form [14]. Natural trimers isolated from amniotic
fluid have been shown to have reduced binding affinity
for IAV [14] and a reduced ability to neutralize the virus
or to potentiate neutrophil respiratory burst responses to
IAV [15]. The functional significance of the Thr/Ala160
polymorphism is unclear. Most of our prior studies using
recombinant SP-D have involved the Thr11, Thr160 form.
In this study we test the antiviral activities of the Met11,
Ala160 form.
SP-D (and other collectins including mannose binding
lectin (MBL), conglutinin and CL43) inhibits IAV by
binding to glycans on the viral envelope proteins. Binding
of these collectins to high mannose oligosaccharides on
the hemagglutinin (HA) appears to be most important for
viral neutralization [16-18]. Of interest, more recent
strains of IAV of the H3N2 and H1N1 human lineages
show greater susceptibility to inhibition by SP-D or MBL
in conjunction with increasing glycosylation of the HA
[19]. The more recent strains also show reduced virulence
in mice. Similar findings were obtained in an elegant
study involving reverse genetics to add or remove glycans
from the HA of the human H3N2 subtype [20].
The goals of the current study were to evaluate antiviral
activities of recombinant full length SP-D of the Met11,
Ala160 form and to determine the impact of specific glyc-
osylation sites on the HA of various subtypes of influenza
on susceptibility to inhibition by SP-D.
Materials and methods
Virus Preparations
Influenza strains were grown in the chorioallantoic fluid
of ten day old chicken eggs and purified on a discontinu-
ous sucrose gradient as previously described [21]. The
virus was dialyzed against PBS to remove sucrose, aliq-
uoted and stored at -80°C until needed. Philippines 82/
H3N2 (Phil82), Phil82/BS, Brazil 78 H1N1 (Braz78),
Braz78/BS, and Mem71H-BelN/H3N1 strains were kindly
provided by Dr. E. Margot Anders (Univ. of Melbourne,
Melbourne, Australia). Post thawing the viral stocks con-
tained ~5 × 108 plaque forming units/ml. Other strains
were prepared and tested at St. Jude's Hospital.
SP-D preparations
Recombinant human SP-D having a Met at amino acid 11
(and Ala at amino acid 160) was prepared as described
[22,23]. CHO DHFR cells were used for these prepara-
tions. Superdex was used for the affinity column instead
of maltose agarose for these preparations. Stock concen-
trations of rhSP-D were 0.5 mg/ml in buffer (20 mM Tris,
200 mM NaCl, l mM EDTA pH 7.4). The endotoxin level
of all SP-D preparations was 0.1~0.5 EU/ml (Limulus
Lysate Assay, Cambrex, Walkersville, MD).
SP-D characterization
The SP-D preparations were characterized by matrix-
assisted laser desorption/ionization-time-of-flight mass
spectroscopy (MALDI-TOF MS), SDS PAGE, analytical
ultracentrifugation (AUC), size-exclusion chromatogra-
phy-multi angle light scattering (SEC-MALS), and atomic
force microscopy (AFM). Only the AUC and AFM charac-
terization results are shown here.
Sedimentation velocity characterization of rhSP-D was
performed on a Beckman Optima XLA analytical ultracen-
trifuge at 40 K rpm, 20°C using UV detection. Samples
were at 50 μg/ml in 10 mM HEPES, 150 mM NaCl, 2 mM
EDTA, pH 7.5. Data analysis was performed using SedFit
v9.4 with a confidence level set at 0.95. Results are shown
as a continuous distribution to represent the various
molecular species in each sample.Page 2 of 12
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carried out on a NanoScope instrument (Veeco Instru-
ments, Inc., Plainview, NY) using a scan size of 1 μm and
a scan rate of 1.001 Hz. Samples were placed on fresh
mica grids and images obtained under aqueous phase
conditions using tapping mode.
Hemagglutination (HA) inhibition assay
HA inhibition was measured by serially diluting SP-D
preparations in round bottom 96 well plates (Serocluster
U-Vinyl plates; Costar, Cambridge, MA) using PBS con-
taining calcium and magnesium as a diluent [5]. After
adding 25 μl of IAV, giving a final concentration of 40 HA
units per ml or 4 HA units/well, the IAV/protein mixture
was incubated for 15 min. at room temperature, followed
by addition of 50 μl of human type O (in Table 1) or an
avian (in Table 2; note turkey and chicken gave identical
results) erythrocyte suspension. The minimum concentra-
tion of protein required to fully inhibit the hemaggluti-
nating activity of the viral suspension was determined by
noting the highest dilution of protein that still inhibited
hemagglutination. Inhibition of HA activity in a given
well is demonstrated by absence of formation of an eryth-
rocyte pellet. If no inhibition of HA activity was observed
at the highest protein concentration used then the value is
expressed as > the maximal protein concentration.
Measurement of viral aggregation
Viral aggregation was measured by assessing light trans-
mission through stirred suspensions of IAV as previously
described [24].
Fluorescent focus assay of IAV infectivity
MDCK cell monolayers were prepared in 96 well plates
and grown to confluency. These layers were then infected
with diluted IAV preparations for 45 min. at 37°C in PBS
and tested for presence of IAV infected cells after 7 hrs.
using a monoclonal antibody directed against the influ-
enza A viral nucleoprotein (provided by Dr. Nancy Cox,
CDC, Atlanta, GA) as previously described [25]. IAV was
pre-incubated for 30 min. at 37°C with SP-D or control
buffer, followed by addition of these viral samples to the
MDCK cells.
Neuraminidase (NA) inhibition assay
NA activity of IAV was measured by an enzyme-linked
micro plate assay in which Arachis hypogaea peanut lectin
was used to detect β-D-galactose-N-acetylglucosamine
sequences exposed after the removal of sialic acid from
fetuin [26]. Wells of microtiter plate were coated with 50
μl of fetuin (Sigma F-2379: 20 μl/ml in PBS) overnight at
4°C and washed with PBS. Dilutions of IAV strains with
different concentrations of SP-D were preincubated for 30
min. at 37°C and 50 μl of the mixture was added to fetuin
coated wells and incubated at 37°C for 2 hrs. After the
wells were washed, 50 μl of peroxidase labeled peanut lec-
tin [Sigma L-6135: 20 μl/ml in BSA (0.5%)] was added to
each well for 30 min. at room temperature, followed by
washing and incubation with 50 μl of TMP-peroxidase
(Bio-Rad Labs, Hercules, CA) for 20 min. Finally, 50 μl of
1N H2SO4 was added to the wells and the absorbance was
measured by ELISA plate reader at 450 nm.
Human Neutrophil Preparation
Neutrophils from healthy volunteers were isolated to >
95% purity by using dextran precipitation, followed by
Ficoll-Paque gradient separation for the removal of
mononuclear cells, and then hypotonic lysis to eliminate
any contaminating erythrocytes, as previously described
[21]. Cell viability was determined to be >98% by trypan
blue staining. The isolated neutrophils were resuspended
at the appropriate concentrations in control buffer (PBS)
and used within 2 hours. Neutrophil collection was done
with informed consent as approved by the Institutional
Review Board of Boston University School of Medicine.
Measurement of IAV uptake by neutrophils
Fluorescein isothiocyanate (FITC)-labeled IAV (Phil82
strain) was prepared and uptake of virus by neutrophils
was measured by flow cytometry as described [24,27]. In
brief, IAV was incubated with neutrophils for 30 minutes
at 37°C in presence of control buffer. Trypan blue (0.2
mg/ml) was added to these samples to quench extracellu-
lar fluorescence. Following washing, the neutrophils were
fixed with paraformaldehyde and neutrophil associated
fluorescence was measured using flow cytometry. The
Table 1: HA inhibition of wild type and bovine serum resistant strains of IAV by Met11 rhSP-D
Viral Strain Description HA inhibiting concentration(ng/ml)
Phil82 H3N2 wild type HA 9 ± 3
Phil82/BS Lacks glycan 165 on HA 63 ± 3*
Braz78 H1N1 wild type HA 47 ± 13
Braz78/BS Lacks glycan at 104 on HA 253 ± 22*
Mem71H-BelN Recombinant H3N1 strain 43 ± 9**
Results are mean ± SEM of three experiments with human type O negative erythrocytes.
• = p < 0.04 compared with parental viral strain
• ** p < 0.05 compared with Phil82 strainPage 3 of 12
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sample) was measured.
Statistics
Statistical comparisons were made using Student's paired,
two-tailed t test or ANOVA with post hoc test (Tukey's).
ANOVA was used for multiple comparisons to a single
control.
Results
Size characterization of Met11 recombinant human SP-D
Figure 1A shows the size distribution of an unfractionated
preparation of Met11 rhSP-D characterized by AUC. The
SP-D contains small amounts of trimers (~3 Sv) together
with larger amounts of dodecamers (~6.5 Sv) and high
molecular weight multimers (20–35 Sv). These AUC
results were confirmed by atomic force microscopy
(AFM), ie., small amounts of trimers can be seen inter-
spersed with dodecamers (cruciform structures) and
higher order multimers (Figure 1B). The headgroups of
SP-D, which contain the carbohydrate recognition
domain, can be seen easily, especially on the periphery of
the radially symmetric multimers.
Antiviral activities of the Met11 form of recombinant 
human SP-D
Figure 2 demonstrates that the antiviral activities of this
Met11 SP-D are comparable to those we have previously
reported for dodecamers of Thr11 SP-D [28]. The IAV
strain used in these assays was the wild type human
Phil82 strain of the H3N2 subtype. In brief, the Met11 SP-
D inhibited infectivity and NA activity and caused viral
aggregation. Furthermore, Met11 SP-D increased neu-
trophil uptake of IAV.
Activity of SP-D against bovine serum inhibitor resistant 
strains of IAV
As shown in Table 1, Met11 SP-D also strongly inhibited
HA activity of the Phil82 strain for human Type O eryth-
rocytes. By comparison, SP-D caused less inhibition of the
Table 2: Sensitivity of different influenza strains to inhibition by SP-D and their HA glycan attachments
H3N2 SPD 63 81 122 126 133 144 165 246 276
X31 (Aichi/68xA/PR8) >2 μg + +
A/Udorn/72 >2 μg + +
A/Shandong/9/93 >2 μg + + + + +
A/Wuhan/359/95 >2 μg + + + +
A/Sydney/5/97 62 ng + + + + + +
A/Panama/2007/99 7.8 ng + + + + + + +
A/Fujian/411/02 (rg) 3.9 ng + + + + + + +
Sialic acid distance (Å) 23 28 20 18 7.6 9.8 20 19 43
H1N1 SPD 71 104 142 144 172 177
A/Puerto Rico/8/34 >2 μg
A/Memphis/10/78 3.9 ng + + + +
A/Memphis/7/80 7.8 ng + + + +
A/Memphis/14/96 1 μg + + + +
A/New Caledonia/20/99 >2 μg + + + +
A/Memphis/6/2001 1 μg + + + +
Sialic acid distance (Å) 21 17 15 9 13 24
H1N1 SPD 170 181
A/HK/213/03 2 μg +
A/Vietnam/1203/04 >2 μg + +
Sialic acid distance (Å) 15 27
Notes:
1. SPD masses refer to amount required in hemagglutination inhibition assay to inhibit influenza-mediated agglutination of chicken and turkey red 
blood cells.
2. Numbers refer to amino acid number in the influenza HA "head"; "+" indicates potential N-linked glycosylation site based on sequence. Bold 
numbers indicate residues with large apparent influence on interaction of virus with SP-DPage 4 of 12
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Size distributions of Met11, Ala160 SP-DFigure 1
Size distributions of Met11, Ala160 SP-D. Molecular size distribution of an unfractionated Met11 rhSP-D preparation was 
determined using (A) analytical ultracentrifugation, and (B) atomic force microscopy. Both methods show a distribution of 
trimers, dodecamers and higher molecular weight multimers.
Respiratory Research 2008, 9:65 http://respiratory-research.com/content/9/1/65Phil82/BS strain. The Phil82/BS strain was derived by cul-
turing the parental strain in presence of bovine serum
inhibitors (later shown to largely be the collectin, conglu-
tinin) [29]. The Phil82/BS strain lacks an oligomannose
glycan on the tip of the HA at position 165. Of note, how-
ever, loss of this glycan did not eliminate sensitivity to
Met11 SP-D, implying that other glycans on the HA head
may mediate binding to SP-D as well. A similar strain was
derived from Brazil 78 H1N1 (Braz78) by growth in pres-
ence of bovine serum (called Braz78/BS). Compared to
the parental strain, the Braz78/BS strain lacks an oligosac-
charide attachment at residue 104 on the HA [29]. The
Braz78/BS strain required significantly higher concentra-
tions of Met11 SP-D for inhibition than the Braz78 paren-
tal strain; however, as in the case of Phil82/BS, Braz78/BS
was inhibited indicating that glycans other that at 104 can
mediate binding and inhibition by SP-D. The Mem71H-
BelN/H3N1 strain was significantly less sensitive to inhibi-
tion by SP-D than Phil82. these results led us to try to
determine which glycan attachments on the HA of H1 or
Antiviral activities of Met11 SP-DFigure 2
Antiviral activities of Met11 SP-D. (A) SP-D inhibited infectivity of the Phil82 IAV strain. SP-D also (B) inhibited neuramin-
idase activity, (C) caused viral aggregation, and (D) increased viral uptake by neutrophils. All results are mean ± SEM of at least 
three independent experiments.
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Respiratory Research 2008, 9:65 http://respiratory-research.com/content/9/1/65H3 viral strains are important in binding SP-D, apart from
the important ones at 165 on H3 and 104 on H1.
Chronological analysis of HA glycosylation and susceptibility to 
inhibition by SP-D
Table 2 shows concentrations of SP-D needed to inhibit
chronologically listed H3N2, H1N1, and H5N1 IAV
strains. The table also shows the sites of N-linked glyco-
sylation on the HA "head" of these strains. Note that all
H3N2 strains have a glycan at 165 [30]. The parental
Phil82 strain has glycans at 63, 126, 144, 165, and 246 on
the HA head. There is a progressive increase in glycan
attachments and susceptibility of H3N2 strains to SP-D
over time. The Aichi68 strain (with HA of the initial pan-
demic strain) has attachments only at 81 and 165 and was
resistant to inhibition by SP-D in these assays (at least up
to 2 μg/ml). Based on a correlation of SP-D sensitivity and
glycan position, glycan attachments at 122, 133, and 144
appear to be most strongly associated with sensitivity to
SP-D. Because glycans 122 and 133 appear together
chronologically and correlate with increased sensitivity, at
least one of these positions would appear to be important
for SP-D binding. Figure 3A shows the location of these
three sites with respect to the sialic acid binding site of the
HA. Amino acids 133 and 144 in particular are 7.6 and 9.8
Angstroms distant from the sialic acid binding site, and
may therefore play a more important role in neutraliza-
tion by SP-D than residues 122 and 165, which are 20A
distant.
A somewhat different chronological pattern is evident
with the H1N1 isolates (Table 2). H1 numbering was used
for denoting glycan attachment sites in Table 2. In general
there is a substantial increase in glycosylation on the H1
HA head region comparing strains from early in the 20th
century (e.g., see PR-8 strain) and those circulating since
the re-introduction of H1N1 in 1977. The PR-8 strain and
the 1918 pandemic strain [31] had no glycan sites on the
HA head, and PR-8 is fully resistant to SP-D. Although we
could not test them, the 1918 strains were most likely also
resistant. In contrast, there are 4 glycan attachments on
the HA head of all the more recent strains, including at
least one oligomannose attachment [30]. Note that all
H1N1 strains since 1977 have the glycan at 104 that is lost
in the Braz79/BS strain. Strains isolated in 1978–1980
were highly sensitive to SP-D in our analysis, whereas
unexpectedly more recent strains (we tested strains from
1996–2001) were less sensitive. By correlating glycan
attachments with sensitivity to SP-D, it appears that gly-
cans at 144 and 172 are important for inhibition by SP-D.
These sites were present in the most sensitive strains and
are exchanged for sites at 71 and 142 in the more recent,
less sensitive strains. Figure 3B shows that the 144 and
172 sites are located closer to the sialic acid binding site
than 71 and 142.
We also tested the ability of SP-D to inhibit human H5N1
isolates. Both strains of H5N1 were resistant to SP-D.
These strains have 1 or 2 glycans on the HA head but as
shown in Figure 3C and Table 2, these are not proximal to
the sialic acid binding site.
Discussion
Most of our prior work on functional interactions of
recombinant SP-D with IAV involved the Thr11, Thr160
polymorphic form. We now demonstrate that the Met11,
Ala160 form also has strong viral neutralizing activity. In
addition, both forms of SP-D cause NA inhibition and
virus aggregation and increase neutrophil uptake of the
virus. These findings are reasonable given that the trimeric
lectin domains of the variants have identical structure.
The recombinant SP-D strongly inhibited recent H3N2
and H1N1 strains of IAV and a recent influenza B strain as
well (data not shown). The loss of an oligomannose
attachment at 165 in H3N2 caused marked but not com-
plete loss in sensitivity to SP-D as previously reported
using other forms of SP-D. Of interest, all wild type strains
of H3N2 have this attachment and early studies using the
Memphis72 H3N2 strain showed that the sites at 165 and
285 are oligomannose and that at 81 was complex [32].
Hence, despite having the oligomannose site at 165, early
strains of H3N2 were at least partially resistant to SP-D. It
should be noted that we did obtain slightly different
results using avian (Table 2) vs. human (Table 1) erythro-
cytes in the HA inhibition assay. Using human erythro-
cytes there was some inhibition of the early H3 strains
(Mem71H-BelN) but no inhibition was found for compa-
rable strains using avian cells. In any case the overall
trends were similar with increased activity against the
more recent H3N2 strains.
Abe et al. tested the effects of adding HA head glycans in
the naturally occurring sites on the H3 HA on receptor
binding and fusion activity and reactivity with antisera
[33]. Although the additional glycans reduced receptor
binding affinity, they did not alter fusion activity and they
reduced the ability of antisera raised against early H3N2
strains to bind to the HA. Similarly, Skehel et al. showed
that addition of the glycan at 63 caused loss of reactivity
with an inhibitory monoclonal antibody [34]. Hence, one
plausible explanation for the accumulation of glycan
attachments on the H3 HA is their ability to shield the HA
from antibody-mediated neutralization. This may explain
the apparently paradoxical trend to increased sensitivity
to SP-D. Vigerust et al. have used reverse genetics to test
the effect of adding glycans to a 1968 H3N2 strain. Addi-
tion of the 63, 126, and 246 sites resulted in a virus more
readily inhibited by SP-D and less pathogenic for mice.
Further addition of sites at 133 and 144 did not cause a
greater increase in sensitivity to SP-D. The overall trend ofPage 7 of 12
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Location of added N-linked glycans on the HA head domains of H3, H1 and H5 hemagglutininsFigure 3
Location of added N-linked glycans on the HA head domains of H3, H1 and H5 hemagglutinins. The structures of 
the H1, H3, and H5 HA monomer head regions are shown as white ribbons with the Ca atoms of the corresponding glycosyla-
tion sites listed in Table 2 highlighted as colored balls. PDB1RVZ coordinates of the 1934 H1N1 HA complexed with LSTc 
trisaccharide [31], PDB1HGG coordinates of the X31 H3N2 HA complexed with (a2-3)sialyllactose [38], and PDB12FK0 coor-
dinates of the 2004 Vietnamese H5N1 HA [39] were displayed using Accelrys DS Visualizer 1.7. The trisaccharide (a2-3)sialyl-
lactose was modeled into the H5N1 structure by superpositioning the H5N1 structure onto that of H3N2 structure 
complexed with (a2-3) sialyllactose to illustrate the primary sugar binding site on HA. Increased sensitivity to inhibition by SP-
D appears to correlate with acquisition of certain added glycans on the HA head region (see Table 2). The Ca atoms of these 
sensitive glycan positions are depicted as magenta balls while the other glycan Ca atoms are shown as blue balls. Although the 
glycan at 122 in H3 (purple ball) was identified as potentially important based on hemagglutination inhibition, it is significantly 
further removed from the sialic acid binding site (and therefore less likely to be important) than the glycans at 133 and 144. 
The trisaccharide sugars are depicted as red sticks.
Respiratory Research 2008, 9:65 http://respiratory-research.com/content/9/1/65increased sensitivity with increased glycosylation sites is
consistent with our results and with those of Reading et al.
[19]. We found the greatest increase in sensitivity to SP-D
in strains having glycans at 122, 133 and 144 and show
that these sites (especially 133 and 144) are in close prox-
imity to the sialic acid binding site. Putting our results
together with those of Vigerust et al, inhibition by SP-D
appears to involve having several additional glycan
attachments on the HA head apart from the important site
at 165.
It is unknown at present the type of glycans present at sites
other than 285, 165 and 81. If some are oligomannose
this would provide an obvious explanation for their
importance in binding to SP-D. If not, another hypothesis
is that initial tethering of SP-D occurs by initial binding to
the site at 165. Once bound, SP-D can then interact with
less favorable sites (e.g, to complex glycans terminated
with galactose or hybrid glycans). Another possibility is
that the presence of additional glycans reduces binding
affinity of the HA to sialic acid receptors rendering it more
easy for SP-D to interfere with attachment of the virus to
cells. Further studies will be needed to clarify these possi-
bilities.
Using crystal structures coordinates of the H3 and SP-D
trimers, Figure 4A demonstrates that when these trimers
are aligned along their three-fold axes, the carbohydrate
recognition domains of the SP-D trimer are positioned to
interact with one or both of the glycans at positions 133
and 144 on the HA head, consistent with the deductions
from the hemagglutination data that these two glycan are
involved in the sensitivity of the H3N2 strains to inhibi-
tion by SP-D. This alignment also demonstrates that the
glycan at position 122 is less likely to be important for
interacting with SP-D. Figure 4B shows that the alignment
of the carbohydrate recognition domain of SP-D with the
glycans at 133 and 144 results in the masking of the sialic
acid binding site of HA (red), providing a molecular level
explanation for the sensitivity of the H3N2 strain to
hemagglutination inhibition by SP-D. Analogous struc-
tures and conclusions were obtained for H1N1 and resi-
dues 144 and 172 (data not shown).
Although the alignment shown in Figure 4 represents a
possible interaction between SP-D and HA trimers, it is
important to note that other interactions are also possible.
For example, it is possible that a single SP-D trimer could
act as a "bridge" between adjacent HA trimers on the viral
envelope (or even possibly between HA and NA). It is also
possible that other glycans on HA could be accessed by a
single arm of the SP-D trimer. However, given the nearly
perfect alignment of carbohydrate recognition domains of
the SP-D trimer with glycans 133 and 144 of the HA
trimer Figure 4A), suggests that interactions of this type
are energetically most favorable.
We could not test H2N2 strains, but it is of interest that
these strains had only 2 glycans on the HA head (neither
of which was oligomannose) [35] and may, therefore,
have been resistant to SP-D. The H2 HA was limited in its
ability to add additional glycans to the head since added
glycans not only inhibited receptor binding but also
fusion and infectivity [36]. It is speculated that this limita-
tion may have restricted the ability of H2N2 strains to sur-
vive longer in the human population since they could not
protect themselves against antibody attack. The H3N2 lin-
eage seems to have been able to achieve a better balance
in which strains are protected from antibody-mediated
neutralization (and possibly attenuated in their severity
somewhat by virtue of increased sensitivity to SP-D)
allowing persistence over a longer period in the human
population.
The H1 lineage is also somewhat distinctive from the H3
and H2 lineages. Originally the 1918 strains (like most
duck and swine strain H1N1 strains) [37] lacked glycans
on the HA head. The re-emergence of H1N1 in 1977 was
associated with the addition of 4 new glycan attachments
on the HA head. Since then the human H1N1 lineage has
continued to have 4 such glycans but their locations have
shifted (i.e., sites at 144 and 172 were lost and sites at 71
and 142 added). The site at 104, like that at 165 in the
H3N2 lineage, is apparently important for tethering of SP-
D but other glycans on the HA head are involved in inter-
actions with SP-D. Based on our results it appears that
attachments at 144 and 172 are more effective in mediat-
ing effects of SP-D than 71 and 142 and this fits with the
relative proximity of these sites to the sialic acid binding
site on the HA. Reverse genetic analysis of the role of spe-
cific glycans on the H1 HA, combined with studies of sen-
sitivity to collectins and antibodies, would be of great
interest.
It is of potentially great importance that the H5N1 strains
were not susceptible to SP-D (and that the 1918 H1N1
strain is predicted to not be sensitive) since this could be
one factor accounting for the clinical severity of infection
with these strains.
Conclusion
Overall our results show that the Met11 form of SP-D has
strong antiviral and opsonizing activities. Using this prep-
aration we show that there is a correlation between glycan
attachments on the head of the HA and the susceptibility
of IAV to inhibition by SP-D that implicates specific sites
on the HA as important in binding to SP-D. Of note, pan-
demic strains (e.g., strains of H3N2 and H1N1 isolated
shortly after introduction into the human population)Page 9 of 12
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Alignment of the H3 hemagglutinin (HA) trimer with the neck and carbohydrate recognition domains (NCRD) of an SP-D trimerFigure 4
Alignment of the H3 hemagglutinin (HA) trimer with the neck and carbohydrate recognition domains 
(NCRD) of an SP-D trimer. (A) The structure of X31 H3N2 complexed with (a2-3) sialyllactose (red sticks) [38] was 
aligned with that of the N-terminal carbohydrate recognition domain (NCRD) of SP-D complexed with maltose [40] using 
Accelrys DS Visualizer 1.7. The distance between the C1 atom of one glucose unit of maltose (dark magenta sticks) and the 
corresponding Ca atom of position 133 or 144 (light magenta balls) was within 18 to 20 Angstroms for all three monomeric 
interactions. This distance can be covered by an asparagine side chain plus three or more glycan units, suggesting that a glycan 
originating from either position 133 or 144 of HA can fit into the glycan binding pocket of SP-D and simultaneous interaction 
by all three monomers are possible. The Ca atoms of position 122 (purple balls) are too far (~30 angstroms) from the corre-
sponding the C1 atoms of glucose units bound to SP-D, and unlike positions 133 and 144, the path of 122 to that glucose is 
blocked by a fold in the hemagglutinin structure. Each monomer of HA and SP-D is shown as ribbons with different colors 
matching each monomeric interaction. (B) The side view of the aligned HA and SP-D trimers in (A) was turned approximately 
90 degrees to generate an axial view from the SP-D stem in which the trimeric hemagglutinin is shown as white ribbons while 
the trimeric SP-D is depicted as green ribbons. Binding by SP-D to the glycans originating at the Ca atoms at position 133 or 
144 (light magenta balls) of hemagglutinin would completely block the ability of HA to bind to cellular sialic acid targets (red 
sticks). Alignment of the H1 hemagglutinin based on its positions 144 and 172 onto the NCRD of SP-D yielded similar conclu-
sions.
Respiratory Research 2008, 9:65 http://respiratory-research.com/content/9/1/65and human H5N1 strains are largely resistant to SP-D. The
H3 HA has evolved to have persistently increased HA gly-
cosylation and sensitivity to SP-D, whereas the H1 HA
showed greater sensitivity in the 1970's and 1980's and
has become less sensitive despite maintenance of 4 glycan
sites on the HA. Further studies of H5N1 or H1N1 subtype
viruses using reverse genetics to modify HA glycan sites
should be undertaken to more precisely determine the
role of specific glycans in susceptibility to SP-D.
Competing interests
CP, SB, RJM, and RKS hold shares and/or stock options of
Genzyme Corporation. KLH, MRW, TT, and ECC have no
competing interests.
Authors' contributions
KLH participated in writing the manuscript, designing
experiments and interpreting results. RW carried out the
hemagglutination assays. MRW carried out some of the
hemagglutination inhibition assays (Table 1) and assays
in figure 2. TT performed some of assays shown in figure
2. CP carried out the structural alignments of SP-D and
influenza HA. SB characterized the rhSP-D by AUC and
other methods. RJM helped clone and produce the rhSP-
D and participated in experimental design. ECC assisted
in the experimental plan, interpretation of results and
editing of the manuscript. RKS conceived the study,
designed and coordinated experiments, interpreted results
and helped write the manuscript. All authors read and
approved the final manuscript.
Acknowledgements
The authors would like to thank Charles Morgan for help extracting struc-
tural information regarding the HA glycans, and Jennifer Nietupski and 
Sarah Foster for help with the AFM. This research was supported by NIH 
grants HL-06931 (KLH) and HL-44015 and HL-29594 (ECC).
References
1. Tumpey TM, Maines TR, Van Hoeven N, Glaser L, Solorzano A, Pap-
pas C, Cox NJ, Swayne DE, Palese P, Katz JM, et al.: A two-amino
acid change in the hemagglutinin of the 1918 influenza virus
abolishes transmission.  Science 2007, 315(5812):655-659.
2. Stevens J, Corper AL, Basler CF, Taubenberger JK, Palese P, Wilson
IA: Structure of the uncleaved human H1 hemagglutinin
from the extinct 1918 influenza virus.  Science 2004,
303(5665):1866-1870.
3. Kandel R, Hartshorn K: Prophylaxis and treatment of influenza
virus infection.  Bio Drugs 2001, 2001:303-323.
4. LeVine AM, Whitsett JA, Hartshorn KL, Crouch EC, Korfhagen TR:
Surfactant protein D enhances clearance of influenza A virus
from the lung in vivo.  J Immunol 2001, 167(10):5868-5873.
5. Hartshorn KL, Crouch EC, White MR, Eggleton P, Tauber AI, Chang
D, Sastry K: Evidence for a protective role of pulmonary sur-
factant protein D (SP-D) against influenza A viruses.  J Clin
Invest 1994, 94:311-319.
6. Crouch EC, Smith K, McDonald B, Briner D, Linders B, McDonald J,
Holmskov U, Head J, Hartshorn K: Species differences in the car-
bohydrate binding preferences of surfactant protein D.  Am J
Respir Cell Mol Biol 2006, 35(1):84-94.
7. Crouch E, Tu Y, Briner D, McDonald B, Smith K, Holmskov U, Hart-
shorn K: Ligand specificity of human surfactant protein D:
expression of a mutant trimeric collectin that shows
enhanced interactions with influenza A virus.  J Biol Chem 2005,
280(17):17046-17056.
8. Hawgood S, Brown C, Edmondson J, Stumbaugh A, Allen L, Goerke J,
Clark H, Poulain F: Pulmonary collectins modulate strain-spe-
cific influenza a virus infection and host responses.  J Virol 2004,
78(16):8565-8572.
9. Giannoni E, Sawa T, Allen L, Wiener-Kronish J, Hawgood S: Sur-
factant proteins A and D enhance pulmonary clearance of
Pseudomonas aeruginosa.  Am J Respir Cell Mol Biol 2006,
34(6):704-710.
10. Zhang L, Hartshorn K, Crouch E, Ikegami M, Whitsett J: Comple-
mentation of pulmonary abnormalities in SP-D (-/-) mice
with an SP-D/Conglutinin fusion protein.  J Biol Chem 2002,
277:22453-22459.
11. Floros J, Lin H, Garcia A, Salazar M, Guo X, DiAngelo S, Montano M,
Luo J, Pardo A, Selman M: Surfactant protein marker alleles
identify a subgroup of tuberculosis patients in a Mexican pop-
ulation.  J Infect Dis 2000, 182:1473-1478.
12. LahtI M, Lofgren J, Martilla T, Renko M, Klaavenuniemi T, Haataja R,
Ramet M, Hallman M: Surfactant Protein D Gene Polymor-
phism Associated with Severe Respiratory Syncytial Virus
Infection.  Pediatr Res 2002, 51(6):696-699.
13. Sorensen GL, Hjelmborg JB, Kyvik KO, Fenger M, Hoj A, Bendixen C,
Sorensen TI, Holmskov U: Genetic and environmental influ-
ences of surfactant protein D serum levels.  Am J Physiol Lung
Cell Mol Physiol 2006, 290(5):L1010-1017.
14. Leth-Larsen R, Garred P, Jensenius H, Meschi J, Hartshorn K, Madsen
J, Tornoe I, Madsen HO, Sorensen G, Crouch E, et al.: A common
polymorphism in the SFTPD gene influences assembly, func-
tion, and concentration of surfactant protein D.  J Immunol
2005, 174(3):1532-1538.
15. Hartshorn KL, White MR, Tecle T, Tornoe I, Sorensen GL, Crouch
EC, Holmskov U: Reduced influenza viral neutralizing activity
of natural human trimers of surfactant protein D.  Respir Res
2007, 8:9.
16. Hartshorn K, White M, Voelker D, Coburn J, Zaner K, Crouch E:
Mechanism of binding of surfactant surfactant protein D to
influenza A viruses: importance of binding to hemagglutinin
to antiviral activity.  Biochemical Journal 2000, 351:449-458.
17. Hartshorn KL, Holmskov U, Hansen S, Zhang P, Meschi J, Mogues T,
White MR, Crouch EC: Distinctive anti-influenza properties of
recombinant collectin 43.  Biochem J 2002, 366(Pt 1):87-96.
18. Hartshorn KL, Sastry K, White MR, Anders EM, Super M, Ezekowitz
RA, Tauber AI: Human mannose-binding protein functions as
an opsonin for influenza A viruses.  J Clin Invest 1993,
91:1414-1420.
19. Reading P, Morey L, Crouch E, Anders E: Collectin-mediated anti-
viral host defense of the lung: evidence from influenza virus
infection of mice.  J Virol 1997, 71:8204-8212.
20. Vigerust DJ, Ulett KB, Boyd KL, Madsen J, Hawgood S, McCullers JA:
N-linked glycosylation attenuates H3N2 influenza viruses.  J
Virol 2007, 81(16):8593-8600.
21. Hartshorn KL, Collamer M, Auerbach M, Myers JB, Pavlotsky N, Tau-
ber AI: Effects of influenza A virus on human neutrophil cal-
cium metabolism.  J Immunol 1988, 141(4):1295-1301.
22. Ikegami M, Scoville EA, Grant S, Korfhagen T, Brondyk W, Scheule
RK, Whitsett JA: Surfactant Protein-D and Surfactant Inhibit
Endotoxin-Induced Pulmonary Inflammation.  Chest 2007,
132(5):1447-1454.
23. Ikegami M, Carter K, Bishop K, Yadav A, Masterjohn E, Brondyk W,
Scheule RK, Whitsett JA: Intratracheal recombinant surfactant
protein d prevents endotoxin shock in the newborn preterm
lamb.  Am J Respir Crit Care Med 2006, 173(12):1342-1347.
24. Hartshorn KL, Sastry K, Brown D, White MR, Okarma TB, Lee Y,
Tauber AI: Conglutinin acts as an opsonin for influenza A
viruses.  J Immunol 1993, 151:1-9.
25. Hartshorn K, Sastry K, Chang D, White M, Crouch E: Enhanced
antinfluenza activity of a recombinant pulmonary surfactant
protein D and serum conglutinin fusion protein.   Am J Physiol
Lung Cell Mol Physiol 2000, 278(1):L90-L98.
26. Tecle T, White MR, Crouch EC, Hartshorn KL: Inhibition of influ-
enza viral neuraminidase activity by collectins.  Arch Virol 2007,
152(9):1731-1742.
27. Hartshorn K, White M, Shepherd V, Reid K, Jensenius J, Crouch E:
Mechanisms of anti-influenza activity of pulmonary sur-Page 11 of 12
(page number not for citation purposes)
Respiratory Research 2008, 9:65 http://respiratory-research.com/content/9/1/65Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
factant proteins A and D: comparison with other collectins.
Amer J Physiol 1997, 273:L1156-1166.
28. Hartshorn K, Chang D, Rust K, White M, Heuser J, Crouch E: Inter-
actions of recombinant human pulmonary surfactant pro-
tein D and SP-D multimers with influenza A.  Am J Physiol 1996,
271(5 Pt 1):L753-762.
29. Hartley CA, Jackson DC, Anders EM: Two distinct serum man-
nose-binding lectins function as beta inhibitors of influenza
virus: identification of bovine serum beta inhibitor as conglu-
tinin.  J Virol 1992, 66(7):4358-4363.
30. Basak S, Pritchard DG, Bhown AS, Compans RW: Glycosylation
sites of influenza viral glycoproteins: characterization of
tryptic glycopeptides from the A/USSR(H1N1) hemaggluti-
nin glycoprotein.  J Virol 1981, 37(2):549-558.
31. Gamblin SJ, Haire LF, Russell RJ, Stevens DJ, Xiao B, Ha Y, Vasisht N,
Steinhauer DA, Daniels RS, Elliot A, et al.: The structure and
receptor binding properties of the 1918 influenza hemagglu-
tinin.  Science 2004, 303(5665):1838-1842.
32. Ward CW, Gleeson PA, Dopheide TA: Carbohydrate composi-
tion of the oligosaccharide units of the haemagglutinin from
the Hong Kong influenza virus A/Memphis/102/72.  Biochem J
1980, 189(3):649-652.
33. Abe Y, Takashita E, Sugawara K, Matsuzaki Y, Muraki Y, Hongo S:
Effect of the addition of oligosaccharides on the biological
activities and antigenicity of influenza A/H3N2 virus hemag-
glutinin.  J Virol 2004, 78(18):9605-9611.
34. Skehel JJ, Stevens DJ, Daniels RS, Douglas AR, Knossow M, Wilson IA,
Wiley DC: A carbohydrate side chain on hemagglutinins of
Hong Kong influenza viruses inhibits recognition by a mono-
clonal antibody.  Proc Natl Acad Sci USA 1984, 81(6):1779-1783.
35. Brown LE, Ward CW, Jackson DC: Antigenic determinants of
influenza virus hemagglutinin–IX. The carbohydrate side
chains from an Asian strain.  Mol Immunol 1982, 19(2):329-338.
36. Tsuchiya E, Sugawara K, Hongo S, Matsuzaki Y, Muraki Y, Li ZN,
Nakamura K: Effect of addition of new oligosaccharide chains
to the globular head of influenza A/H2N2 virus haemaggluti-
nin on the intracellular transport and biological activities of
the molecule.  J Gen Virol 2002, 83(Pt 5):1137-1146.
37. Inkster MD, Hinshaw VS, Schulze IT: The hemagglutinins of duck
and human H1 influenza viruses differ in sequence conserva-
tion and in glycosylation.  J Virol 1993, 67(12):7436-7443.
38. Sauter NK, Hanson JE, Glick GD, Brown JH, Crowther RL, Park SJ,
Skehel JJ, Wiley DC: Binding of influenza virus hemagglutinin to
analogs of its cell-surface receptor, sialic acid: analysis by
proton nuclear magnetic resonance spectroscopy and X-ray
crystallography.  Biochemistry 1992, 31(40):9609-9621.
39. Stevens J, Blixt O, Tumpey TM, Taubenberger JK, Paulson JC, Wilson
IA: Structure and receptor specificity of the hemagglutinin
from an H5N1 influenza virus.  Science 2006,
312(5772):404-410.
40. Shrive AK, Tharia HA, Strong P, Kishore U, Burns I, Rizkallah PJ, Reid
KB, Greenhough TJ: High-resolution structural insights into lig-
and binding and immune cell recognition by human lung sur-
factant protein D.  J Mol Biol 2003, 331(2):509-523.Page 12 of 12
(page number not for citation purposes)
